相关实验视频

Updated: Jun 27, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

NCI 159456 作为肺癌向治疗的PERK抑制剂:一个体外研究

Wioletta Rozpędek-Kamińska¹, Grzegorz Galita¹, Natalia Siwecka¹

¹Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 90-419 Lodz, Poland.

|April 27, 2024

概括

一种选择性PERK抑制剂,NCI 159456,通过诱导亡和DNA损伤,有效地向非小细胞肺癌 (NSCLC) 细胞. 这种化合物对NSCLC的向疗法有前途,对正常的肺细胞的影响最小.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞应激反应的应激反应

背景情况:

非小细胞肺癌 (NSCLC) 的预后不佳,五年生存率为15%.
细胞内膜网膜 (ER) 应激和PERK介导的展开蛋白质响应 (UPR) 途径与NSCLC的发病有关.
增加的PERK通路活性与积极的NSCLC表型,复发和不良结果相关.

研究的目的:

研究选择性PERK抑制剂NCI 159456对NSCLC细胞的体外生物效应.
评估NCI 159456对正常人肺纤维细胞 (HPF) 的影响,以评估安全性.

主要方法:

在正常和ER压力条件下用NCI 159456对A549NSCLC细胞和HPF进行处理.
对促亡和抗亡基因表达的分析 (ATF4,DDIT3,BAX,BCL-2).
评估细胞活力,DNA损伤,卡斯巴-3活性和活性氧物种 (ROS) 水平.

主要成果:

在A549细胞中,NCI 159456显著上调了亲亡的基因和下调了抗亡的基因.
抑制剂降低了A549细胞活力,增加了DNA损伤,诱导了亡,并提高了ROS水平.
NCI 159456在测试度中显示出对正常HPF细胞的最小毒性.

结论:

珀克抑制剂NCI 159456有效诱导NSCLC细胞的亡和DNA损伤,无论是正常的还是ER压力.
NCI 159456具有良好的安全性,对正常的肺纤维细胞的影响有限.
用像NCI 159456这样的抑制剂准PERK通路代表了NSCLC的潜在治疗策略.

关键词:

压力ERER压力ERER压力一个叫Perk的Perk.这是一种PERK抑制剂.通过UPR进行全日制检查.灭症 (apoptosis) 是一种死亡的过程.肺癌是一种肺癌.肺癌的治疗方法肺癌的治疗方法

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...